Rescue of Heart Failure by Mitochondrial Recovery

키워드

참고문헌 (71)

1. Bui AL, "Epidemiology and risk profile of heart failure", Nat Rev Cardiol, 8, pp.30~41 (2011)
2. Levy D, "Long-term trends in the incidence of and survival with heart failure", N Engl J Med, 347, pp.1397~1402 (2002)
3. Sowers JR, "Diabetes, hypertension, and cardiovascular disease: an update", Hypertension, 37, pp.1053~1059 (2001)
4. Gheorghiade M, "Navigating the crossroads of coronary artery disease and heart failure", Circulation, 114, pp.1202~1213 (2006)
5. Chen HM, "Bladder pain syndrome", interstitial cystitis increase the risk of coronary heart disease, 2014, pp.33, 511~515
6. Kuzmicic J, "Mitochondrial dynamics: a potential new therapeutic target for heart failure", Rev Esp Cardiol, 64, pp.916~923 (2011)
7. Jubert Marquez, "Definitely not lost in translation: post-translational modifications of cardiac mitochondrial proteins in cardiovascular disease", Korean Circulation Journal, 46(1), pp.1~12 (2016), 대한심장학회[DOI]
8. Doenst T, "Cardiac metabolism in heart failure:implications beyond ATP production", Circ Res, 113, pp.709~724 (2013)
9. Witt H, "Sex-specific pathways in early cardiac response to pressure overload in mice", J Mol Med (Berl), 86, pp.1013~1024 (2008)
10. Faerber G, "Induction of heart failure by minimally invasive aortic constriction in mice: reduced peroxisome proliferator-activated receptor γ coactivator levels and mitochondrial dysfunction", J Thorac Cardiovasc Surg, 141, pp.492~500.e1 (2011)
11. Sebastiani M, "Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies", J Am Coll Cardiol, 50, pp.1362~1369 (2007)
12. Lee SR, "Mitochondrial DNA, mitochondrial dysfunction, and cardiac manifestations", Front Biosci (Landmark Ed), 21, pp.1410~1426 (2016)
13. Sun CK, "Losartan preserves integrity of cardiac gap junctions and PGC-1alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction", Int Heart J, 48, pp.533~546 (2007)
14. Garnier A, "Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles", J Physiol, 551(Pt 2), pp.491~501 (2003)
15. Li H, "Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy", Proc Natl Acad Sci U S A, 97, pp.3467~3472 (2000)
16. Wang J, "Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression", Nat Genet, 21, pp.133~137 (1999)
17. Moens AL, "Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure", J Mol Cell Cardiol, 51, pp.564~569 (2011)
18. Graham BH, "A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart", muscle isoform of the adenine nucleotide translocator, 1997, pp.16, 226~234
19. Li Y, "Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase", Nat Genet, 11, pp.376~381 (1995)
20. Hansson A, "A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts", Proc Natl Acad Sci U S A, 101, pp.3136~3141 (2004)
21. Rosca MG, "Mitochondrial dysfunction in heart failure", Heart Fail Rev, 18, pp.607~622 (2013)
22. Yi Cai, "EGCG Blocked Phenylephrin-Induced Hypertrophy in H9C2 Cardiomyocytes, by Activating AMPK-Dependent Pathway", The Korean Journal of Physiology & Pharmacology, 19(3), pp.203~210 (2015), 대한약리학회
23. Duncker DJ, "Endothelial nitric oxide synthase and cardiac remodelling: location, location, location0?", Cardiovasc Res, 93, pp.383~385 (2012)
24. Yanagishita T, "Protective effect of captopril on ischemic myocardium", Jpn Circ J, 61, pp.161~169 (1997)
25. Sun W, "Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: a PRISMA-compliant network metaanalysis", Medicine (Baltimore), 95, pp.2554~ (2016)
26. Lai YC, "SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction", Circulation, 133, pp.717~731 (2016)
27. Benes J, "Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats", Clin Sci (Lond), 121, pp.29~41 (2011)
28. Yin M, "Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure", Am J Physiol Heart Circ Physiol, 301, pp.H459~H468 (2011)
29. Gundewar S, "Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure", Circ Res, 104, pp.403~411 (2009)
30. Yasunori Suematsu, "LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice", European Journal of Heart Failure, 18(4), pp.386~393 (2016), Wiley-Blackwell[DOI]
31. Solomon SD, "Influence of ejection fraction on outcomes and efficacy of sacubitril", valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial, 2016, pp.9, e002744~
32. Yao K, "Carvedilol promotes mitochondrial biogenesis by regulating the PGC-1", TFAM pathway in human umbilical vein endothelial cells (HUVECs), 2016, pp.470, 961~966
33. DeVore AD, "Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: findings from the OPTIMIZE-HF registry", Am Heart J, 173, pp.172~178 (2016)
34. De Toni L, "Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo", J Endocrinol Invest, 34, pp.738~741 (2011)
35. Schwartz BG, "Cardiac uses of phosphodiesterase-5 inhibitors", J Am Coll Cardiol, 59, pp.9~15 (2012)
36. Moens AL, "Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy", Circulation, 117, pp.2626~2636 (2008)
37. Chong E, "Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K", AKT, Heart Rhythm, pp.2015, 12[DOI]
38. Biala A, "Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes", Blood Press, 19, pp.196~205 (2010)
39. Hafstad AD, "Novel aspects of ROS signalling in heart failure", Basic Res Cardiol, 108, pp.359~ (2013)
40. Burgoyne JR, "Redox signaling in cardiac physiology and pathology", Circ Res, 111, pp.1091~1106 (2012)
41. Tsutsui H, "Oxidative stress and mitochondrial DNA damage in heart failure", Circ J, 72(Suppl A), pp.A31~A37 (2008)
42. Olsen RK, "Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism", J Inherit Metab Dis, 38, pp.703~719 (2015)
43. Lu Z, "PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload", Antioxid Redox Signal, 13, pp.1011~1022 (2010)
44. Bayeva M, "Mitochondrial dysfunction and oxidative damage to sarcomeric proteins", Curr Hypertens Rep, 12, pp.426~432 (2010)
45. Kwon SH, "H(2)O(2) regulates cardiac myocyte phenotype via concentrationdependent activation of distinct kinase pathways", J Mol Cell Cardiol, 35, pp.615~621 (2003)
46. Siwik DA, "Regulation of matrix metalloproteinases by cytokines and reactive oxygen", nitrogen species in the myocardium, 2004, pp.9, 43~51
47. Goyal BR, "Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy", Acta Cardiol, 67, pp.203~211 (2012)
48. Dizon LA, "Exercise perspective on common cardiac medications", Integr Med Res, 2, pp.49~55 (2013)
49. Davogustto G, "Perhexiline, Cardiac energetics, and heart failure: lessons from the first law of thermodynamics", JACC Heart Fail, 3, pp.659~660 (2015)
50. Zorov DB, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release", Physiol Rev, 94, pp.909~950 (2014)
51. Williams GS, "Mitochondrial calcium and the regulation of metabolism in the heart", J Mol Cell Cardiol, 78, pp.35~45 (2015)
52. Brustovetsky N, "Mitochondrial ADP", ATP carrier can be reversibly converted into a large channel by Ca2+, 1996, pp.35, 8483~8488
53. Baines CP, "Voltage-dependent anion channels are dispensable for mitochondrialdependent cell death", Nat Cell Biol, 9, pp.550~555 (2007)
54. Leung AW, "The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition", J Biol Chem, 283, pp.26312~26323 (2008)
55. Solesio ME, "Inorganic polyphosphate (polyP) as an activator and structural component of the mitochondrial permeability transition pore", Biochem Soc Trans, 44, pp.7~12 (2016)
56. Nazareth W, "Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A", J Mol Cell Cardiol, 23, pp.1351~1354 (1991)
57. Griffiths EJ, "Protection by cyclosporin A of ischemia", reperfusion-induced damage in isolated rat hearts, 1993, pp.25, 1461~1469
58. Nakagawa T, "Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death", Nature, 434, pp.652~658 (2005)
59. Periasamy M, "Calcineurin and the heartbeat, an evolving story", J Mol Cell Cardiol, 34, pp.259~262 (2002)
60. Schreiber SL, "The mechanism of action of cyclosporin A and FK506", Immunol Today, 13, pp.136~142 (1992)
61. Griffiths EJ, "Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion", Biochem J, 307(Pt 1), pp.93~98 (1995)
62. Argaud L, "Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury", J Mol Cell Cardiol, 38, pp.367~374 (2005)
63. Gomez L, "Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice", Am J Physiol Heart Circ Physiol, 293, pp.H1654~H1661 (2007)
64. Clarke SJ, "Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A", J Biol Chem, 277, pp.34793~34799 (2002)
65. Javadov SA, "Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition", Cardiovasc Res, 45, pp.360~369 (2000)
66. Shao H, "Dose-dependent protective effect of propofol against mitochondrial dysfunction in ischaemic", reperfused rat heart: role of cardiolipin, 2008, pp.153, 1641~1649
67. Rajesh KG, "Antioxidant MCI-186inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression", Am J Physiol Heart Circ Physiol, 285, pp.H2171~H2178 (2003)
68. Clements-Jewery H, "Mitochondria, the calcium uniporter, and reperfusion-induced ventricular fibrillation", Br J Pharmacol, 149, pp.811~813 (2006)
69. Javadov S, "NHE-1 inhibition-induced cardioprotection against ischaemia", reperfusion is associated with attenuation of the mitochondrial permeability transition, 2008, pp.77, 416~424
70. Villa-Abrille MC, "Silencing of cardiac mitochondrial NHE1 prevents mitochondrial permeability transition pore opening", Am J Physiol Heart Circ Physiol, 300, pp.H1237~H1251 (2011)
71. Liddy KA, "Functional decorations: posttranslational modifications and heart disease delineated by targeted proteomics", Genome Med, 5, pp.20~ (2013)

관련 논문AI추천